regavirumab
cytomegaloviremia
cytoplasmic polyhedrosis virus
sevirumab
cyanomyovirus
cystovirus
cyanopodovirus
gancyclovir
immunovirus
libivirumab
intetumumab
amlitelimab
cilgavimab
cyclovirus
bavituximab
suvizumab
carlumab
maribavir
ansuvimab
palivizumab
tixagevimab
cytomegaly
aquabirnavirus
olendalizumab
zanolimumab
heterophile antibody
glembatumumab
immunocytofluorometry
heterophil antibody
Forssman antibody
microantibody
pancytokeratin
neoantigen
cytomegalovirus
cypovirus
polyvaccine
scytovirin
evolocumab
soravtansine
clenoliximab
ipilimumab
HIV
antinucleosome
avdoralimab
phage
DNAemia
vaccinia
multinucleopolyhedrovirus
fomivirsen
ozoralizumab
tucotuzumab
acute retroviral syndrome
elotuzumab
sonepcizumab
vapaliximab
maculavirus
gammapapillomavirus
maslimomab
naptumomab estafenatox
panitumumab
AIDS-related complex
bivatuzumab
ocrelizumab
hartmanivirus
imdevimab
robatumumab
monovaccine
mapatumumab
carlavirus
alphapolyomavirus
siltuximab
felvizumab
brolucizumab
intrabody
pidilizumab
abagovomab
ravulizumab
gevokizumab
cyanophage
olaratumab
tislelizumab
samalizumab